One-Stop Comprehensive Solution for In Vitro Immunogenicity Assessment
Release Date:
2025-11-06 16:06
With the rapid advancement of biotechnology-based therapeutics—including therapeutic proteins, monoclonal antibodies, and cell and gene therapies—immunogenicity assessment has become an indispensable and critical component of drug development and clinical safety monitoring. Immunogenicity refers to the phenomenon in which the body recognizes therapeutic protein drugs as foreign antigens, thereby triggering an immune response. Unnecessary or unexpected immune reactions can severely compromise a drug’s safety and efficacy.
In the immunogenicity risk assessment framework, in vitro assays have emerged as a core evaluation method due to their high throughput, high sensitivity, strong controllability, and alignment with the 3Rs principle of animal welfare—replacement, reduction, and refinement.
Immunogenicity is a complex biological process that begins with the recognition of a drug by the immune system and can subsequently elicit a wide range of clinical outcomes—ranging from transient, clinically insignificant non-neutralizing antibodies to persistent, high-titer neutralizing antibodies, and even life-threatening systemic allergic reactions. Unintended immune responses can lead to the production of anti-drug antibodies (ADAs), including binding antibodies, neutralizing antibodies, immune complexes, and anti-idiotypic antibodies. These ADAs not only may neutralize the biological activity of the drug and alter its pharmacokinetic profile but also can result in reduced or complete loss of therapeutic efficacy.
Causes of immunogenicity:
1. Drug-related
The drug is murine- or human-derived.
Mechanism of drug action
Molecular Structure and Modifications
Form a polymer
Contains impurities
2. Patient-related
Patient’s immune status
Allergy history
Genetic background
3. Treatment Plan-Related
Route of administration
Dosage
Dosage frequency
For protein- or peptide-based therapeutic biologics, the induction of immunogenicity can, to a certain extent, reduce drug efficacy, shorten the drug’s half-life or decrease its exposure, and even pose significant risks to medication safety. For vaccine-type products such as peptides or mRNA-based vaccines, both excessively strong and insufficient immunogenicity can directly impact both efficacy and safety.
Leveraging a mature immunogenicity technology service platform, Hycells Biotechnology offers more precise immune cell profiling services during the early stages of drug development and provides in vitro immunogenicity pre-screening solutions for large-molecule drugs, RNA-based therapeutics, peptides, adjuvants, stem cells, and other classes of biologics. By drawing on core resources such as PBMC sample banks, dendritic cell and T-cell samples, and post-DC screening samples, and integrating proprietary products with specialized technical service platforms, Hycells Biotechnology has established a comprehensive “three-in-one” service system dedicated to delivering end-to-end, one-stop in vitro immunogenicity assessment solutions for its clients.
Solution
T cells serve as a central hub in immunogenic responses: they not only directly mediate cellular immunity but also act as critical drivers in initiating humoral immunity—such as ADA and NAb antibody responses—and in establishing immunological memory. Consequently, their in vitro assessment is of paramount importance.
In vitro restimulation assay of peripheral blood mononuclear cells
Principle: PBMCs are isolated from healthy donors or patients and stimulated in vitro with the test drug. Their immunogenicity is assessed by measuring activation and proliferation markers on T cells.
Validate data sharing
mRNA drugs (COVID-19 molecules)
Peptide drugs
Antibody drugs
PBMC system
DC activation
DC activation
Platform-derived specialty products
PBMC Cell Bank
DC Cell Induction Kit
1. No monocyte sorting required; PBMC-based culture system; easy to operate.
2. Rapid induction in 3–7 days, shortening the experimental timeline.
3. The DC cell recovery rate reaches 30%–70%, outperforming imported brands.
4. Leveraging a PBMC library for preliminary screening and validation to minimize the impact of individual variability and enhance assay stability.
5. Domestic spot products with stable supply.
Serum-free cell cryopreservation solution
1. Safety: Serum-free and free of xenogeneic components.
2. Application: Suitable for the storage of immune cells and stem cells, with particularly excellent cryopreservation results for NK cells and γδ T cells.
3. High efficiency: Excellent cell recovery rates, with viability exceeding 90% for a wide range of cell t
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board